I don't think this is a short selling issue.
Look at bio tech as a group, the entire group is getting hammered in the last few weeks. Add in patent issues and you have nothing but negative headwinds with ACOR until they have some good news to deliver. I'd like to get in this around $25.00
It still amazes me how the hedge funds with big short positions can force the stock price of a company down.Like I said before,if Kyle Bass is short the stock you own,you've got problems.Eventually,the fundamentals of the company bring the price back up,but it can be really painful trying to hang on while it's under attack from the shorts.I still like ACOR a lot.Thinking of buying more.
I guess THAT didn't happen. Kyle Bass is killing ACOR, I hope the company can withstand the patent onslaught and recover through improving sales and margins. I am worried about it though. And #marketmaker79, I have thought long ago that BIIB would acquire them but of that has not panned out.
As someone who has shorted ACOR multiple times over the years, all I can say is be careful! I found myself cashing in any time a made a thousand or more, but the pain when it spiked was far worse.
Over the last 18 months, I'm more inclined to go long. I think it's a great acquisition target, that's ultimately why I covered and shy'd away.
I'm seriously thinking of shorting this stock. Bass and the powerful hedge funds have taken out companies time after time. I believe they will influence this stock as well. I've been long but this is dangerous. Any opinions?
Hayman Capital seeks to invalidate patents while betting on a drop in target’s shares
By JOSEPH WALKER and ROB COPELAND
Updated April 7, 2015 7:24 p.m. ET
A well-known hedge-fund manager is taking a novel approach to making money: filing and publicizing patent challenges against pharmaceutical companies while also betting against their shares.-Wall Street Journal
Doesn't seem ethical to me.
"Patients with MS consistently rate walking as the most important function they want to maintain, regardless of what stage they are in their disease. Walking impairment is directly associated with loss of independence, restrictions on a patient's ability to work and a reduction in overall levels of household income. In fact, a research survey shows that 88 per cent of sampled Canadians living with MS report that difficulty walking affects their overall mobility.
"For patients with MS, one of the greatest areas affected in their lives is walking. Until fampridine SR (Fampyra), there have been no pharmacologic agents shown to directly improve walking function in persons with multiple sclerosis," said Dr. Christine Short, Associate Professor, Department of Medicine, Division of Physical Medicine and Rehabilitation, Dalhousie University, Halifax, NS. "As a clinician who manages persons with multiple sclerosis, the approval of this treatment in Canada represents a real breakthrough in our battle to help individuals maintain independence and quality of life in the face of a progressive neurologic disease.""
Definitely, there was a long-felt and unsolved need.
ACOR patents are valid.
"the court outlined examples of factors that show "objective evidence of nonobviousness". They are:
2.long-felt but unsolved needs; and
3.failure of others"
AMPYRA sales in 2014 was $366.2 million.
AMPYRA addressed a critical unmet need for people with multiple sclerosis (MS): improving their walking.
I see that Hayman Bass is in the news again. So again i say, this type of challenge will continue. Hayman Capitol is using a new process called "inter party review.' Acorda gets most of their revenue from Ampra, a treatment for multiple sclerosis. One common ingredient was once used as bird poison. The petition if accepted, may allow eight other generic firms to also challenge Ampra's patents. But even if Hayman is successful in their partition against Ampra, it's still has protection until 2027. Acorda also has other drugs in the pipeline plus acquisitions on tap. Their is no reason for the drop in stock price. Earnings were excellent and should continue.jmo Les
Sentiment: Strong Buy